J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Markowitz, J.
Right arrow Articles by Risch, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Markowitz, J.
Right arrow Articles by Risch, S.

Articles

Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine

JS Markowitz, CL DeVane, DW Boulton, HL Liston, and SC Risch

Olanzapine is an atypical antipsychotic medication indicated for the treatment of schizophrenia and other manifestations of psychotic illness. Common side effects include somnolence, constipation, weight gain, and postural hypotension. The authors report a case of hypotension accompanied by bradycardia in a normal, healthy volunteer participating in an olanzapine pharmacokinetic study following a single 5 mg dose. A venous catheter allowed for serial blood sampling of olanzapine concentrations before, during, and after the adverse event. The subject experienced a rapid absorption of the drug and higher than anticipated maximum plasma concentrations. This case suggests that atypical antipsychotics, although generally better tolerated than conventional agents, may still result in untoward reactions that may be partially due to individual differences in drug absorption and metabolism.


This article has been cited by other articles:


Home page
J Clin PharmacolHome page
J. S. Markowitz, C. L. DeVane, R. J. Malcolm, H. A. Gefroh, J.-S. Wang, H.-J. Zhu, and J. L. Donovan
Pharmacokinetics of Olanzapine After Single-Dose Oral Administration of Standard Tablet Versus Normal and Sublingual Administration of an Orally Disintegrating Tablet in Normal Volunteers
J. Clin. Pharmacol., February 1, 2006; 46(2): 164 - 171.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
C.-Y. Wang, Z.-J. Zhang,, W.-B. Li, Y.-M. Zhai, Z.-J. Cai, Y.-Z. Weng, R.-H. Zhu, J.-P. Zhao, and H.-H. Zhou
The Differential Effects of Steady-State Fluvoxamine on the Pharmacokinetics of Olanzapine and Clozapine in Healthy Volunteers
J. Clin. Pharmacol., July 1, 2004; 44(7): 785 - 792.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American College of Clinical Pharmacology